PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+0.37%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.56B
AUM Growth
+$1.56B
(-5.6%)
Cap. Flow
-$16.8M
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
77.78%
Holding
44
New
2
Increased
8
Reduced
7
Closed
7
Top Buys
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$19.1M |
| 2 |
eHealth
EHTH
|
$12M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$6.97M |
| 4 |
Biogen
BIIB
|
$5.61M |
| 5 |
Alkermes
ALKS
|
$3.82M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$17.3M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
$15M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$11.1M |
| 4 |
AstraZeneca
AZN
|
$10M |
| 5 |
Puma Biotechnology
PBYI
|
$9.77M |
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Financials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $196M | 12.49% | 2,212,950 | – | – |
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $186M | 11.91% | 519,033 -30,787 | -6% | -$11.1M |
|
3
Insmed
INSM
$28.8B
| $164M | 10.49% | 6,025,706 +6,600 | +0.1% | +$180K |
|
4
United Therapeutics
UTHR
$13.8B
| $148M | 9.49% | 687,206 | – | – |
|
5
Amicus Therapeutics
FOLD
$2.34B
| $117M | 7.47% | 10,114,043 | – | – |
|
6
STAAR Surgical
STAA
$1.36B
| $104M | 6.65% | 1,140,511 | – | – |
|
|
7
Biogen
BIIB
$19.4B
| $92.4M | 5.9% | 385,000 +23,400 | +6% | +$5.61M |
|
8
Prothena Corp
PRTA
$441M
| $83.3M | 5.32% | 1,685,282 | – | – |
|
|
RVNC
9
DELISTED
Revance Therapeutics, Inc.
RVNC
| $71.3M | 4.56% | 4,369,366 +1,167,500 | +36% | +$19.1M |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $54.6M | 3.49% | 2,337,877 | – | – |
|
|
11
Vanda Pharmaceuticals
VNDA
$279M
| $44.5M | 2.84% | 2,834,244 -957,561 | -25% | -$15M |
|
|
12
eHealth
EHTH
$118M
| $41.2M | 2.63% | 1,615,570 +469,700 | +41% | +$12M |
|
13
Align Technology
ALGN
$10.3B
| $36.4M | 2.33% | 55,405 | – | – |
|
14
Karyopharm Therapeutics
KPTI
$61.7M
| $35.2M | 2.25% | 5,470,452 +87,400 | +2% | +$562K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $33.3M | 2.13% | 781,730 +163,800 | +27% | +$6.97M |
|
|
GRTS
16
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $30.3M | 1.94% | 2,356,282 | – | – |
|
17
Gossamer Bio
GOSS
$562M
| $20.1M | 1.28% | 1,772,950 | – | – |
|
|
18
Alkermes
ALKS
$4.78B
| $17.5M | 1.12% | 754,200 +164,300 | +28% | +$3.82M |
|
19
AnaptysBio
ANAB
$569M
| $15.2M | 0.97% | 436,592 | – | – |
|
|
EPZM
20
DELISTED
Epizyme, Inc
EPZM
| $13.7M | 0.88% | 5,485,213 -1,371,300 | -20% | -$3.43M |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $13.1M | 0.84% | 598,900 +154,000 | +35% | +$3.37M |
|
22
Kezar Life Sciences
KZR
$28.9M
| $11M | 0.7% | 656,200 | – | – |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.8M | 0.69% | 3,997,826 -486,585 | -11% | -$1.32M |
|
24
Cytokinetics
CYTK
$4.23B
| $5.64M | 0.36% | 123,686 | – | – |
|
25
Travere Therapeutics
TVTX
$1.56B
| $5.16M | 0.33% | 166,069 | – | – |
|